Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center
Research

JCCC Member Directory

Elizabeta Nemeth, Ph.D.
Elizabeta Nemeth, Ph.D.

Affiliation(s):

Assistant Professor, Department of Medicine, Pulmonary and Critical Care Medicine
Member, JCCC Hematopoietic Malignancies Program Area

Contact Information:

Phone:
(310) 825-7499
E-mail:

Scientific Interest(s):

Dr. Elizabeta Nemeth is interested in regulation of iron metabolism and the pathogenesis of iron disorders. There are multiple interactions between iron metabolism and cancer. On one hand, iron overload promotes carcinogenesis. At the other end of the spectrum, cancer-related inflammation leads to iron-restriction, hypoferremia and anemia of cancer. Her goal is to understand the interactions between cancer and iron metabolism and use the knowledge to develop appropriate therapeutic interventions.

Selected Cancer-Related Publications:

Lin L, Valore EV, Nemeth E, Goodnough JB, Gabayan V, Ganz T. Iron-transferrin regulates hepcidin synthesis in primary hepatocyte culture through hemojuvelin and BMP2/4. Blood. 2007.

Origa R, Galanello R, Ganz T, Giagu N, Maccioni L, Faa G, Nemeth E. Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica. 2007; 92(5): 583-8.

De Domenico I, Ward DM, Langelier C, Vaughn MB, Nemeth E, Sundquist WI, Ganz T, Musci G, Kaplan J. The Molecular Mechanism of Hepcidin-mediated Ferroportin Down-Regulation. Mol Biol Cell. 2007.

Semrin G, Fishman DS, Bousvaros A, Zholudev A, Saunders AC, Correia CE, Nemeth E, Grand RJ, Weinstein DA. Impaired intestinal iron absorption in Crohn's disease correlates with disease activity and markers of inflammation. Inflamm Bowel Dis. 2006; 12(12): 1101-6.

De Domenico I, McVey Ward D, Nemeth E, Ganz T, Corradini E, Ferrara F, Musci G, Pietrangelo A, Kaplan J. Molecular and clinical correlates in iron overload associated with mutations in ferroportin. Haematologica. 2006; 91(8): 1092-5.